EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Reply to “Urine-based detection of HPV for cervical cancer screening: towards clinical implementation”

Sharmila Manjeshwar iD, Noah Kojima iD, Eric Tsang, David Pereira, Emmanuel Silva, Ha Duong, Felix Chao, Daniel R Marshak, Ricky Y T Chiu iD, Jeffrey D Klausner iD

Journal of Clinical Microbiology · 08.04.2026 · 64 (4)

DOI: 10.1128/jcm.00162-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Microbiology, erschienen am 08.04.2026. Verfasst von Sharmila Manjeshwar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Phase Scientific Americas, Garden Grove, California, USA. Die Arbeit nennt 2 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

W e thank the authors for their interest in our report describing a novel, urine-based test for the detection of cervical human papillomavirus infection (HPV) (1). It is well understood that early detection of high-risk HPV infection is important to prevent cervical cancer, and we believe that urine-based HPV testing is a promising non-invasive alternative to traditional cervical cancer screening approaches. We agree with the authors’ comments regarding the potential impact of urine collection volume on analytical sensitivity, and that larger first-void volumes may dilute HPV DNA. We want to highlight that our proprietary PHASiFY technology-based extraction method is uniquely designed to concentrate DNA from large sample input volumes, thereby counteracting the dilution effects that are seen when traditional DNA extraction methods are used for large urine volumes (i.e., over 30 mL). As a result, variations in collection volume do not impact the ability of this technology to extract nucleic acids as long as the concentrations are at or above the lower limit of detection (15–30 copies/mL) as determined in our analytical studies. We would like to clarify that the Phase HPV Urine Test is standardized for 40 mL urine sample collection for routine patient testing in the Clinical Laboratory Improve­ ment Amendments (CLIA) laboratory. This standardized volume is supported by product development and verification studies to be the optimal volume of sample that retains the analytical sensitivity/low limit of detection and high overall percent agreement with the reference method. However, in the validation study described in this report, the rationale for collecting up to 100 mL was to have sufficient volume for two separate DNA extractions (40 mL urine each) at two different time points from the same patient sample. The results from the stability study indicate that in this “worst-case scenario,” the samples of up to 100 mL still demonstrated high concordance with the reference method; and HPV detection between

Autor:innen und Institutionen

  • Phase Scientific Americas, Garden Grove, California, USA.
  • Department of Medicine, University of California, Los Angeles, California, USA.
  • Phase Scientific International Ltd, Hong Kong, China.
  • Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

ORCID-Profile: Sharmila Manjeshwar, Noah Kojima, Ricky Y T Chiu, Jeffrey D Klausner

Zitieren

APA

Manjeshwar, S., Kojima, N., Tsang, E., Pereira, D., Silva, E., Duong, H., Chao, F., Marshak, D. R., Chiu, R. Y. T., & D Klausner, J. (2026). Reply to “Urine-based detection of HPV for cervical cancer screening: towards clinical implementation”. Journal of Clinical Microbiology, 64(4). https://doi.org/10.1128/jcm.00162-26

Vancouver

Manjeshwar S, Kojima N, Tsang E, Pereira D, Silva E, Duong H, et al. Reply to “Urine-based detection of HPV for cervical cancer screening: towards clinical implementation”. Journal of Clinical Microbiology. 2026;64(4). doi:10.1128/jcm.00162-26

BibTeX
@article{Manjeshwar2026,
  author = {Manjeshwar, Sharmila and Kojima, Noah and Tsang, Eric and Pereira, David and Silva, Emmanuel and Duong, Ha and Chao, Felix and Marshak, Daniel R and Chiu, Ricky Y T and D Klausner, Jeffrey},
  title = {Reply to “Urine-based detection of HPV for cervical cancer screening: towards clinical implementation”},
  journal = {Journal of Clinical Microbiology},
  year = {2026},
  volume = {64},
  number = {4},
  doi = {10.1128/jcm.00162-26}
}
Kostenlos starten →